triiodothyronine has been researched along with Lymphoma in 13 studies
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.
Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.
| Excerpt | Relevance | Reference |
|---|---|---|
| "When the lymphoma was in remission, her circulating T3 concentration was 2-55 nmol/l but when it relapsed it fell to 0-55 nmol/l." | 5.26 | Inhibition of conversion of thyroxine to triiodothyronine in patients with severe chronic illness. ( Carter, JN; Corcoran, JM; Eastmen, CJ; Lazarus, L, 1976) |
| " A cytotoxic effect of this system on a line of mouse ascitic lymphoma cells (LSTRA) is demonstrated here using four different assay systems: 51Cr release, trypan blue exclusion, inhibition of glucose C-1 oxidation, and loss of oncogenicity for mice." | 3.65 | Peroxidase-H2O2-halide system: Cytotoxic effect on mammalian tumor cells. ( Clark, RA; Einstein, AB; Fefer, A; Klebanoff, SJ, 1975) |
| "Children with cancer were also evaluated after antineoplasic treatment (CAT, n = 17)." | 1.38 | Salivary evaluation of pediatric patients with cancer, before and after antineoplasic treatment. ( Brito, CX; Guerra, RN; Liberio, SA; Lima, MV; Mendonça, C; Mouchrek-Filho, JC; Nascimento, FR; Oliveira-Junior, JJ; Paim, DB; Pereira, AL, 2012) |
| "Whenever thyroid lymphoma is suspected, we recommend an ultrasound scan of the thyroid gland and fine needle aspiration biopsy as initial diagnostic procedures." | 1.29 | Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases. ( Ikeda, H; Katayama, S; Kuma, K; Matsuzuka, F; Miyauchi, A; Narabayashi, I; Sugawara, M, 1993) |
| "The mean thyroid dose for irradiated malignant lymphomas in the prospective and the retrospective group was 45 Gy and 43 Gy respectively." | 1.28 | Incidence of hypothyroidism after irradiation of the neck with special reference to lymphoma patients. A retrospective and prospective analysis. ( Becker, W; Feyerabend, T; Kapp, B; Reiners, C; Richter, E, 1990) |
| "When the lymphoma was in remission, her circulating T3 concentration was 2-55 nmol/l but when it relapsed it fell to 0-55 nmol/l." | 1.26 | Inhibition of conversion of thyroxine to triiodothyronine in patients with severe chronic illness. ( Carter, JN; Corcoran, JM; Eastmen, CJ; Lazarus, L, 1976) |
| "The non-surgical treatment of thyroid cancer is outlined." | 1.25 | The non-surgical treatment of thyroid cancer. ( Halnan, KE, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (53.85) | 18.7374 |
| 1990's | 5 (38.46) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guerra, RN | 1 |
| Oliveira-Junior, JJ | 1 |
| Mouchrek-Filho, JC | 1 |
| Liberio, SA | 1 |
| Lima, MV | 1 |
| Paim, DB | 1 |
| Brito, CX | 1 |
| Mendonça, C | 1 |
| Nascimento, FR | 1 |
| Pereira, AL | 1 |
| NIELSEN, PE | 1 |
| RANLOV, P | 1 |
| Matsuzuka, F | 1 |
| Miyauchi, A | 1 |
| Katayama, S | 1 |
| Narabayashi, I | 1 |
| Ikeda, H | 1 |
| Kuma, K | 1 |
| Sugawara, M | 1 |
| Fletcher-Chiappini, SE | 1 |
| Compton, MM | 1 |
| LaVoie, HA | 1 |
| Day, EB | 1 |
| Witorsch, RJ | 1 |
| Comptom, MM | 1 |
| Nakanishi, K | 1 |
| Taniguchi, Y | 1 |
| Onji, M | 1 |
| Worm, AM | 2 |
| Brinckmeyer, LM | 2 |
| Nissen, NI | 2 |
| Halnan, KE | 1 |
| Carter, JN | 1 |
| Eastmen, CJ | 1 |
| Corcoran, JM | 1 |
| Lazarus, L | 1 |
| Clark, RA | 1 |
| Klebanoff, SJ | 1 |
| Einstein, AB | 1 |
| Fefer, A | 1 |
| Feyerabend, T | 1 |
| Kapp, B | 1 |
| Richter, E | 1 |
| Becker, W | 1 |
| Reiners, C | 1 |
| Hershman, JM | 1 |
| Eriksen, E | 1 |
| Kaufman, N | 1 |
| Champlin, RE | 1 |
| Kirkegaard, C | 1 |
| Hasselbalch, H | 1 |
| Faber, J | 1 |
| Poulsen, S | 1 |
| Bregengård, C | 1 |
| Hasselstrøm, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Critical Illness Stress-induced Immune Suppression Prevention Trial[NCT00395161] | Phase 3 | 293 participants (Actual) | Interventional | 2007-04-30 | Terminated (stopped due to Terminated for futility on 11/30/09 based on the recommendation of the DSMB) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00395161)
Timeframe: 28 days after admission to the PICU
| Intervention | participants (Number) |
|---|---|
| Enteral Zinc, Selenium, Glutamine, and IV Metoclopramide | 15 |
| Enteral Whey Protein, IV Saline | 8 |
(NCT00395161)
Timeframe: 48 hours after admission until PICU discharge
| Intervention | Days (Median) |
|---|---|
| Enteral Zinc, Selenium, Glutamine, and IV Metoclopramide | 1 |
| Enteral Whey Protein, IV Saline | 2 |
What is reported is the number of participants with counts qualifying as lymphopenia. (NCT00395161)
Timeframe: from time of PICU admission till discharge from PICU
| Intervention | participants (Number) |
|---|---|
| Enteral Zinc, Selenium, Glutamine, and IV Metoclopramide | 5 |
| Enteral Whey Protein, IV Saline | 12 |
(NCT00395161)
Timeframe: 48 hours after PICU admission till discharge from PICU
| Intervention | Mean number of events per 100 study days (Mean) |
|---|---|
| Daily Nutriceutical Supplementation | 4.99 |
| Whey Protein | 4.83 |
(NCT00395161)
Timeframe: 48 hours after admission until 5 days after discharged from the PICU
| Intervention | Days (Median) |
|---|---|
| Daily Nutriceutical Supplementation | 12.1 |
| Whey Protein | 13.2 |
1 review available for triiodothyronine and Lymphoma
| Article | Year |
|---|---|
MYXOEDEMA COMA. TWO CASE REPORTS AND A REVIEW.
Topics: Autoimmune Diseases; Coma; Geriatrics; Humans; Hydrocortisone; Hyponatremia; Hypothermia; Hypothermi | 1964 |
12 other studies available for triiodothyronine and Lymphoma
| Article | Year |
|---|---|
Salivary evaluation of pediatric patients with cancer, before and after antineoplasic treatment.
Topics: Biomarkers; Blood Glucose; Case-Control Studies; Central Nervous System Neoplasms; Child; Cohort Stu | 2012 |
Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cycl | 1993 |
Glucocorticoid-prolactin interactions in Nb2 lymphoma cells: antiproliferative versus anticytolytic effects.
Topics: Analysis of Variance; Animals; Cell Division; Cell Survival; Dexamethasone; DNA Damage; Dose-Respons | 1993 |
Triiodothyronine enhances expression of the interleukin-2 receptor alpha chain.
Topics: Cells, Cultured; Colforsin; Concanavalin A; Gene Expression; Humans; Killer Cells, Natural; Leukocyt | 1999 |
[Thyroid function in malignant lymphoma].
Topics: Adult; Aged; Female; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, N | 1977 |
Thyroid function in malignant lymphoma.
Topics: Adolescent; Adult; Aged; Female; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; | 1977 |
The non-surgical treatment of thyroid cancer.
Topics: Adenocarcinoma; Age Factors; Aged; Calcitonin; Carcinoma, Papillary; Cell Count; Cell Survival; Chil | 1975 |
Inhibition of conversion of thyroxine to triiodothyronine in patients with severe chronic illness.
Topics: Chronic Disease; Humans; Lymphoma; Myocardial Infarction; Thyrotropin; Thyroxine; Triiodothyronine | 1976 |
Peroxidase-H2O2-halide system: Cytotoxic effect on mammalian tumor cells.
Topics: Animals; Ascitic Fluid; Carbon Dioxide; Carbon Radioisotopes; Carcinogens; Chromium Radioisotopes; F | 1975 |
Incidence of hypothyroidism after irradiation of the neck with special reference to lymphoma patients. A retrospective and prospective analysis.
Topics: Adolescent; Adult; Aged; Child; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Hypothyr | 1990 |
Thyroid function tests in patients undergoing bone marrow transplantation.
Topics: Adult; Anemia, Aplastic; Bone Marrow Transplantation; Female; Humans; Leukemia; Lymphoma; Male; Thyr | 1990 |
Thyroid hormone metabolism in hypermetabolic patients with haematological disorders.
Topics: Adult; Aged; Aged, 80 and over; Female; Hematologic Diseases; Humans; Leukemia; Lymphoma; Male; Midd | 1989 |